Table 1.
Baseline characteristics.
| Outcome measure | Treatment group (n = 34) | Control group (n = 32) | P value |
|---|---|---|---|
| Clinical symptoms | |||
| Morning stiffness score | 3.29 (1.96) | 3.25 (1.67) | 0.99† |
| Tenderness index | 13.47 (7.80) | 13.75 (6.97) | 0.88† |
| Swelling index | 8.97 (6.13) | 8.78 (6.26) | 0.90† |
| VAS | 6.56 (1.46) | 6.69 (1.66) | 0.74† |
| DAS28 | 5.99 (1.20) | 5.98 (1.01) | 0.96† |
|
| |||
| RA serological disease markers | |||
| ESR (mm/60 min) | 52.85 (30.20) | 53.66 (31.37) | 0.92Δ |
| CRP (mg/L) | 16.80 (29.70) | 20.56 (29.27) | 0.56Δ |
| RF (IU/ml) | 167.09 (197.67) | 191.58 (215.65) | 0.41Δ |
Values are represented as mean (SD). †P value by independent samples t test. ΔP value by Mann–Whitney U test. Table 1 shows there were no significant differences in baseline characteristics between the two groups (P > 0.05).